CERo Therapeutics (CERO) Stock Price, News & Analysis

Company Overview

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

Key Stats

• Today's Range: $5.30 to $5.65
• 50-Day Range: $4.68 to $8.92
• 52-Week Range: $4.27 to $895.40
• Volume: 53,607 shs
• Average Volume: 303,801 shs
• Market Capitalization: $6.51 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $45.00
• Consensus Rating: Buy

CERo Therapeutics Stock Analysis - MarketRank™

CERo Therapeutics scored higher than 72% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Buy

Consensus Rating

CERo Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

CERo Therapeutics has a consensus price target of $45.00, representing about 733.3% upside from its current price of $5.40.

Amount of Analyst Coverage

CERo Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: N/A
• Proj. Earnings Growth: N/A

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.33% of the float of CERo Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

CERo Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CERo Therapeutics has recently increased by 8.26%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CERo Therapeutics does not currently pay a dividend.

Dividend Growth

CERo Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.33% of the float of CERo Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

CERo Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CERo Therapeutics has recently increased by 8.26%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.59

News Sentiment

CERo Therapeutics has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.93 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for CERo Therapeutics this week, compared to 2 articles on an average week.

Search Interest

10 people have searched for CERO on MarketBeat in the last 30 days. This is an increase of 233% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added CERo Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CERo Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.72% of the stock of CERo Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 29.64% of the stock of CERo Therapeutics is held by institutions.

CERO Stock Analysis - Frequently Asked Questions

How have CERO shares performed this year?

CERo Therapeutics' stock was trading at $120.00 at the beginning of 2025. Since then, CERO stock has decreased by 95.5% and is now trading at $5.40.

How were CERo Therapeutics' earnings last quarter?

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) announced its quarterly earnings data on Friday, August, 22nd. The company reported ($61.71) EPS for the quarter, beating analysts' consensus estimates of ($70.23) by $8.52.

When did CERo Therapeutics' stock split?

CERo Therapeutics shares reverse split before market open on Friday, June 13th 2025.The 1-20 reverse split was announced on Wednesday, June 11th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 12th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of CERo Therapeutics?

Shares of CERO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of CERo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CERo Therapeutics investors own include Verve Therapeutics (VERV), Lithium Americas (LAC), NVIDIA (NVDA), Maxeon Solar Technologies (MAXN), ARM (ARM), AST SpaceMobile (ASTS) and BigBear.ai (BBAI).

Company Calendar

• Last Earnings: 8/22/2025
• Today: 9/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CERO
• Previous Symbol: NASDAQ:CERO
• CIK: 1870404
• Web: www.cero.bio
• Phone: 215-731-9450
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Price Target and Rating

• Average Price Target for CERo Therapeutics: $45.00
• High Price Target: $60.00
• Low Price Target: $30.00
• Potential Upside/Downside: +733.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.30 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -209.40%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.56
• Quick Ratio: 0.56

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($41.98) per share
• Price / Book: -0.13

Miscellaneous

• Outstanding Shares: 1,205,000
• Free Float: 1,052,000
• Market Cap: $6.51 million
• Optionable: N/A
• Beta: 0.47